Astellas paying $7.3m to settle off-label charges
This article was originally published in Scrip
Executive Summary
Astellas Pharma is ponying up $7.3m to settle charges it violated the US False Claims Act by promoting the use of its echinocandin drug Mycamine (micafungin sodium) for use in pediatric patients before it was approved in that population, the Department of Justice (DOJ) said on 16 April.